Probiotic Oral Delivery Study Service in Animal Models

In Vitro Digestion Models

• Simulated Gastric Fluid (SGF) & Simulated Intestinal Fluid (SIF) Assays: Assessment of probiotic survival and viability under various pH and enzyme conditions mimicking the human GI tract.
• Dynamic Gastrointestinal Models: Advanced in vitro systems providing a more physiologically relevant simulation of digestion, absorption, and microbial fermentation.
• Mucus Adhesion Assays: Quantifying the ability of probiotic strains to adhere to mucin, a critical step for colonization.

In Vivo Animal Models

• Disease Model Efficacy Studies
  
  • Inflammatory Bowel Disease (IBD) Models: DSS-induced colitis, TNBS-induced colitis, genetic models (e.g., IL-10 knockout mice).
  • Infectious Disease Models: C. difficile infection, Salmonella infection, E. coli infection.
  • Metabolic Syndrome/Obesity Models: Diet-induced obesity (DIO) models.
  • Allergy/Asthma Models: Ovalbumin-induced allergy models.
  • Neurological Models: Exploring the gut-brain axis in models of anxiety, depression, or neuroinflammation.
• Gut Colonization and Persistence Studies
  
  • Quantification of probiotic strains in fecal samples, gut contents, and intestinal tissues over time using selective plating, qPCR, or next-generation sequencing.
  • Determination of the duration of colonization and factors influencing persistence.
• Dose-Response Studies
  
  • Identification of optimal probiotic dosages for achieving desired effects.
  • Evaluation of efficacy across a range of concentrations.
• Gut Microbiota Composition and Diversity
  
  • Comprehensive analysis of changes in the host's gut microbiota using 16S rRNA gene sequencing (amplicon sequencing) or metagenomics.

Metabolic Parameter Analysis

• Quantification of short-chain fatty acids (SCFAs) in cecal content or fecal samples using gas chromatography-mass spectrometry (GC-MS).
• Analysis of host metabolic markers (e.g., glucose, insulin, lipids) in serum.

Sample Information

To initiate your study, please provide detailed information about your probiotic product:

• Probiotic Strain(s) Information: Species, strain designation, source, and genetic identity (if available).
• Formulation Details: Lyophilized powder, liquid culture, encapsulated, etc.
• Viability/CFU Count: Current viable cell count (CFU/g or CFU/mL).
• Storage Conditions: Recommended storage temperature and stability data.
• Safety Data: Any existing in vitro or in vivo safety data, including GRAS (Generally Recognized As Safe) status if applicable.
• Targeted Health Benefit: Specific health claims or therapeutic areas you wish to investigate.
• Desired Dose Range: If you have preliminary dose suggestions.

Deliverables

Turnaround Time

The turnaround time for each study is highly dependent on the complexity of the experimental design, the animal model used, the duration of the in vivo phase, and the number of analytical endpoints. A detailed timeline will be provided with your customized proposal.